BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn, will participate in the AGP Summer Healthcare Symposium

Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, has appointed Jim Vasselli, M.D. as the company’s chief medical officer, effective today.

Gamma Biosciences, a global life sciences company serving the advanced therapy market, today announced the appointment of Terry Pizzie as Chief Executive Officer (CEO) of operating company Astrea Bioseparations.

Cognito Therapeutics, announced today its plans to add a second digital therapeutic to the company’s pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimer’s Disease (DS-AD).

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced it has submitted a New Drug Submission (NDS) to Health Canada for AMX0035 (sodium phenylbutyrate (PB)-taurursodiol (TURSO)) for the treatment of ALS

Expansion Therapeutics, Inc., today announced the appointment of Mark Ledeboer, Ph.D. to Senior Vice President of Drug Discovery.

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced that Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will present a corporate overview at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.

Cyclo Therapeutics Announces Inclusion in the Russell 2000 ® Index

DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU ® Initiated in Patients with HER2 Positive Metastatic Breast Cancer.